i3 Verticals (NasdaqGS:IIIV) Q1 2026 Earnings call February 06, 2026 08:30 AM ET Company ParticipantsCharles Nabhan - Managing Director of Equity Research- Payments/FintechClay Whitson - Chief Strategy OfficerGeoff Smith - Chief Financial OfficerGreg Daily - Chairman and CEORick Stanford - PresidentConference Call ParticipantsAlexander Markgraf - AnalystMadison Schurr - Senior Associate/AnalystPeter Heckman - AnalystOperatorGood day, everyone, and welcome to the i3 Verticals first quarter 2026 earnings conf ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Speaker1Good morning, my name is Ruth and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2025 earnings call and business update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star 1 on your ...

AerCap (NYSE:AER) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Speaker6Good day and welcome to AerCap's Q4 2025 financial results. Today's conference is being recorded, and a transcript will be available following the call on the company's website. At this time, I'd like to turn the conference over to Brian Canniffe, Group Treasurer. Please go ahead, sir.Speaker1Thank you, Operator, and hello everyone. Welcome to our fourth quarter 2025 conference call. With me today is our Chief Executive Officer Ae ...

Financial Data and Key Metrics Changes - 2025 was a record year for the company, with fee-related earnings (FRE) up 12% year-over-year, reaching a margin of 47% [4][15] - Total inflows amounted to $54 billion, significantly exceeding the original target of $40 billion, and representing a 32% increase year-over-year [4][16] - Distributable earnings (DE) for 2025 were $1.7 billion, or $4.02 per share, an 11% increase from the previous year [13][15] - Total fee revenues reached a record $2.6 billion for the full year, reflecting a 10% organic growth rate [15] Business Line Data and Key Metrics Changes - Carlyle AlpInvest generated a record $274 million of FRE for the year, up nearly 60% [17] - Global Credit delivered a record $402 million of FRE for 2025, up 21% from the prior year [18] - Global private equity realized over $18 billion of proceeds in 2025, the highest level in the past three years [19] Market Data and Key Metrics Changes - The company was the number 1 private equity sponsor globally by IPO proceeds, generating approximately $10 billion of IPO issuance over the past two years [5][6] - The IPO of Medline raised more than $7 billion, marking it as the largest sponsor-backed IPO of all time [6] - Direct lending had a record quarter of originations, with CLO inflows of $7 billion in 2025, up almost 20% from the prior year [9][10] Company Strategy and Development Direction - The company continues to focus on investment performance, disciplined capital allocation, and delivering long-term value for global investors and shareholders [11] - Strategic investments have been made in global wealth, insurance solutions, and asset-backed finance, with significant opportunities for continued growth [15] - The company plans to host a shareholder update to share multi-year financial targets and insights into its strategic direction [12] Management's Comments on Operating Environment and Future Outlook - Despite recent market volatility, management remains optimistic about the economic engine, citing strong January data indicating good GDP growth and EBITDA generation [25][26] - The company expects continued growth supported by a diversified fundraising pipeline and improving capital markets conditions [20] - Management acknowledges the complexity of the macro environment but believes it is generally constructive for deployment and realization activity [20] Other Important Information - The company returned a record $1.2 billion of capital to shareholders through dividends and share buybacks during 2025 [19] - The balance sheet remains strong, with $2 billion in cash and over $3 billion in investments [19] Q&A Session Summary Question: Thoughts on sustainability of monetization momentum into 2026 - Management is cautious about extrapolating recent market volatility but notes that January data looks promising for GDP growth and margins [25][26] Question: State of play in direct lending and credit - Management feels well-positioned in direct lending and has added key leaders to enhance origination and integration across private credit strategies [32][34] Question: Expectations for management fee growth in 2026 - Management will provide more details in the upcoming shareholder update but emphasizes the diversification in business mix driving success [52][78] Question: Outlook for CLOs in 2026 - The CLO business has performed well, and management expects another active year, although it may not reach the record levels of the past two years [83] Question: Steps to enhance originations in the credit business - The company has built a strong origination team and achieved record originations in 2025, with plans to continue leveraging its capabilities [88][90]

Under Armour (NYSE:UA) Q3 2026 Earnings call February 06, 2026 08:30 AM ET Speaker6Good day, and welcome to the Under Armour third quarter 2026 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw the question, please press sta ...

i3 Verticals (NasdaqGS:IIIV) Q1 2026 Earnings call February 06, 2026 08:30 AM ET Speaker2 Good day, everyone, and welcome to the i3 Verticals first quarter 2026 earnings conference call. Today's call is being recorded, and a replay will be available starting today through February 13th. The number for the replay is 855-669-9658, and the code is 6769466. The replay may be accessed for 30 days at the company's website. At this time, for opening remarks, I would like to turn the call over to Clay Whitson, Chie ...

Mettler-Toledo International (NYSE:MTD) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Speaker9Ladies and gentlemen, thank you for standing by. My name is Jericho, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Mettler-Toledo Fourth Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during ...

Financial Data and Key Metrics Changes - Fourth quarter revenue reached a record $136.5 million, up 11% year-over-year in constant currencies, marking the first sequential revenue growth from Q3 to Q4 since 2017 [18] - Full-year revenue for 2025 was a record $533.1 million, up 5.7% in constant currencies [20] - Non-GAAP gross margin for the fourth quarter was 44.8%, an increase of 140 basis points year-over-year [19] - Non-GAAP earnings per share for the fourth quarter were $0.44, up $0.06 year-over-year [20] Business Line Data and Key Metrics Changes - CNC revenue in the U.S. grew 35% in the fourth quarter and 25% year-over-year for 2025, driven by strong demand in innovation-led industries [18][21] - Injection molding revenue declined 1.9% in 2025, impacted by weakness in medical device demand [21] - 3D printing revenue declined 4.7% year-over-year, although metal 3D printing showed strength with double-digit growth [22] Market Data and Key Metrics Changes - U.S. revenue grew 9.1% year-over-year, while European revenue declined 7% in constant currencies [21] - The company noted strong momentum in data centers and aerospace and defense markets, which are expected to drive future growth [5][6] Company Strategy and Development Direction - The company aims to serve customers across the entire life cycle of a part, from prototype through production, focusing on four strategic pillars: elevate customer experience, accelerate innovation, expand production, and drive operational efficiency [6][10] - The establishment of a global capability center in India is intended to enhance innovation and support global operations [12][56] - The company plans to implement new go-to-market strategies in Europe to stabilize margins and reset the cost base for growth [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for 2026, anticipating a year of transformation and growth, with expectations for revenue growth of 6%-8% [25] - The company is focused on improving customer experience and operational efficiency to drive long-term growth and profitability [10][17] Other Important Information - The company generated $74.5 million in cash from operations in 2025, leading the digital manufacturing industry in cash generation [24] - The company has no debt and ended 2025 with $142.4 million in cash and investments [24] Q&A Session Summary Question: Insights on Q4 performance and sequential growth - Management noted that Q4 saw good order volumes, but January started with a more normalized, softer demand [30] Question: Details on end markets and applications - Management confirmed strong growth in innovation-led markets such as aerospace and defense, with Protolabs positioned as a key partner [33] Question: Strategic initiatives and their timing - Management indicated that the current year is focused on transformation, with results expected to accelerate in the coming years [34] Question: Unique developers and revenue per contact - Management highlighted a focus on increasing revenue per contact, with a 23% increase in Q4 [41] Question: U.S. supply chains for defense - Management acknowledged good exposure to aerospace and defense but did not provide specifics on reshoring discussions [42][45] Question: Injection molding growth visibility - Management is pivoting towards production in injection molding, supported by new certifications and pilot programs with medical device manufacturers [52] Question: Advanced CNC capabilities impact - Management reported early positive performance from newly launched advanced CNC capabilities, indicating customer demand [54] Question: India capability center focus - The India center aims to leverage technical talent to support global business and innovation initiatives [56]

Financial Data and Key Metrics Changes - Fourth quarter net sales were $1.9 billion, down 2.7% year-over-year, and core sales declined 4.1% [17] - Full-year net sales were $7.2 billion, a decline of 5%, and core sales decreased by 4.6% [21] - Normalized gross margin for the fourth quarter was 33.9%, down 70 basis points year-over-year, while normalized operating margin was 8.7%, up 160 basis points [18][19] - Normalized earnings per share for 2025 were $0.57 compared to $0.68 in the prior year [23] Business Line Data and Key Metrics Changes - The Learning and Development segment showed resilience, with strong performance from brands like Sharpie and Expo [9] - The Baby segment improved significantly, with Graco's market share increasing by 160 basis points for the full year and over 350 basis points in the fourth quarter [9] - The Home and Commercial segment faced challenges, particularly in the Kitchen category, but promotional activities and selective price adjustments helped stabilize performance [10] - Outdoor and Recreation segment showed stabilization with improved gross and operating margins as the year progressed [11] Market Data and Key Metrics Changes - Core sales in Argentina grew slightly in the fourth quarter due to economic recovery, while Brazil's core sales were down only mid-single digits [18] - The overall market environment remains challenging, with expectations of a 2% decline in categories for 2026 [12] Company Strategy and Development Direction - The company has focused on rebuilding front-end capabilities and strengthening back-end capabilities while reducing complexity [4] - A global productivity plan was announced to enhance competitiveness and support long-term value creation [6] - The company aims to convert strengthened capabilities into improved performance while maintaining margin and cash discipline [16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2025 was more challenging than anticipated due to tariffs impacting consumer behavior and retail dynamics [5] - The company expects core sales to decline by approximately 2% for 2026 but is confident in outperforming the category due to strong innovation and distribution improvements [12][30] - Management highlighted the importance of innovation, with over 25 Tier 1 and Tier 2 launches planned for 2026 [13] Other Important Information - The company reduced its China sourcing exposure to below 10%, enhancing supply chain resilience [6] - Full-year operating cash flow guidance for 2026 is set at $350-$400 million, reflecting a 40% increase over 2025 [27] Q&A Session Questions and Answers Question: Can you help us understand your level of visibility on shelf space wins and confidence in sales growth? - The company is planning for category declines but expects to outperform due to strong innovation and secured shelf space wins that will kick in starting in Q2 [37][40] Question: Can you elaborate on the pricing interventions in the baby and kitchen categories? - The company adjusted pricing in response to tariff rollbacks and is implementing a 15% price reduction on Rubbermaid EasyStore lids to remain competitive [42][44] Question: What are the expectations for category growth in the long term? - The company anticipates that real income growth and product life cycles will contribute to category recovery, aiming for a long-term growth rate of 2%-3% [58]

Roivant Sciences (NasdaqGS:ROIV) Q3 2026 Earnings call February 06, 2026 08:00 AM ET Company ParticipantsBenjamin Zimmer - CEOMatt Gline - CEOStephanie Lee - Head of Investor RelationsNone - Company RepresentativeConference Call ParticipantsAlexander Thompson - Managing Director, and Senior Equity Research AnalystAshwani Verma - Executive Director of SMID Biotech and Biopharma, and Equity Research AnalystBrian Cheng - Executive Director, and Senior Biotech AnalystCorinne Johnson - Managing Director of Equit ...